Vmbook Online ordering
Biotechnology
Celldex is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of immunotherapies for cancer and other diseases. Here are some key statistics for Celldex Therapeutics (CLDX) and some vital information concerning its earnings and growth:
* Price: The current price of Celldex Therapeutics (CLDX) is around $36.42.
* Market Capitalization: Celldex Therapeutics (CLDX) has a market capitalization of about $2.03 billion.
* Earnings: Celldex Therapeutics (CLDX) disclosed a loss of $0.75 per share for the quarter ending December 31, 2022.
* Revenue: The company reported revenue of $12.40 million for the quarter ending December 31, 2022.
* Growth: Celldex Therapeutics (CLDX) has seen significant growth in its stock price over the past year, rising from around $10 per share to its current price.
* Average Volume: The average trading volume of Celldex Therapeutics (CLDX) shares over the past three months is approximately 1.19 million.
* 52-Week Range: The stock's 52-week range is $2.53 - $40.50.
* Beta: Celldex Therapeutics (CLDX) has a beta of 2.39, indicating that it is more volatile than the overall market.
* Target Price: The average target price of Celldex Therapeutics (CLDX) is around $51.33, indicating a potential upside of around 40% from its current price.
In terms of its pipeline, Celldex Therapeutics is focused on developing immunotherapies for cancer and other diseases. Its most advanced program is glembatumumab vedotin, a possible treatment for breast cancer and other solid tumors. The company is also developing CDX-0158, a potential treatment for tissue injury in systemic sclerosis, and CDX-1140, a possible treatment for ependymoma.
Overall, Celldex Therapeutics (CLDX) is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer and other diseases. While the company has seen significant growth in its stock price over the past year, it is still in its clinical development stage and has yet to generate significant revenue.